Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lithium Americas Corp (LAC) vs Viatris Inc (VTRS) Price & Performance

Lithium Americas CorpTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Lithium Americas Corp vs Viatris Inc — how do they compare? Lithium Americas Corp trades at $3.28 (market cap $1.18B), while Viatris Inc trades at $16.21 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 15.8× Lithium Americas Corp's market cap, and Viatris Inc pays a 2.95% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.

LACVTRS
Market Cap
$1.18B$18.69B
Sector
Basic MaterialsHealth
52-Week High
$10.05$17.86
52-Week Low
$2.71$9.49
Enterprise Value
$1.29B$30.80B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lithium Americas Corp

Lithium Americas Corp. (LAC) trades at $3.30, up 1.54% today, with a bullish technical signal from moving averages but negative profitability metrics including an ROE of -11.35% and net loss of $122.09 million in 2025. Recent news highlights a $175 million financing to strengthen the balance sheet as Thacker Pass approaches peak construction, though earnings have been volatile with mixed quarterly beats and misses.

The outlook is balanced: analyst consensus shows 47% buy ratings with no sells, reflecting optimism on lithium demand, but high execution risk remains given negative cash flow from operations and substantial capital needs. Upside depends on successful project development, while downside risks include funding pressures and commodity price volatility.

Viatris Inc

Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.

Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lithium Americas Corp

Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.

Read more on LAC

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS